This inventor holds 3 USPTO granted patents. Top assignee: Icahn School of Medicine at Mount Sinai. Active years: 2015-2017.
Location History:
- New York, NY (US) (2015 - 2016)
- Beachwood, OH (US) (2017)
Company Filing History:
Years Active: 2015-2017
Title: Goutham Narla: Innovator in Anticancer Therapeutics
Introduction
Goutham Narla is a prominent inventor based in New York, NY (US). He has made significant contributions to the field of cancer research through his innovative patents. With a total of 3 patents, Narla is dedicated to developing new therapeutic methods for treating various forms of cancer.
Latest Patents
Narla's latest patents include groundbreaking work on tricyclic compounds as anticancer agents. These compounds are designed to modulate FOXO transcription factor proteins, offering potential treatments for cancer, age-onset proteotoxicity, stress-induced depression, inflammation, and acne. Another notable patent focuses on methods and compositions for treating cancer, particularly through the use of a combination of anti-EGFR agents and agents that enhance the activity of tumor suppressor genes like KLF6 and FOXO1. This innovative approach aims to treat non-small cell lung cancer, especially in patients with drug resistance to erlotinib, while minimizing central nervous system effects.
Career Highlights
Goutham Narla is affiliated with the Icahn School of Medicine at Mount Sinai, where he continues to advance his research in cancer therapeutics. His work is characterized by a commitment to improving patient outcomes through innovative treatment strategies.
Collaborations
Narla collaborates with esteemed colleagues, including Michael H Ohlmeyer and Matthew David Galsky, to further enhance the impact of his research in the medical community.
Conclusion
Goutham Narla's contributions to cancer research through his innovative patents highlight his dedication to improving therapeutic options for patients. His work exemplifies the importance of innovation in the fight against cancer.